$NBIX
NEUROCRINE BIOSCIENCES INC

2020 Q2 Form 10-Q Financial Statement

#000091447520000018 Filed on August 03, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $302.4M $183.5M $138.4M
YoY Change 64.8% 89.36% 94.69%
Cost Of Revenue $2.400M $1.600M $1.129M
YoY Change 50.0% 87.35% 18.84%
Gross Profit $300.0M $181.9M $137.3M
YoY Change 64.93% 89.38% 95.72%
Gross Profit Margin 99.21% 99.13% 99.18%
Selling, General & Admin $96.50M $80.80M $87.54M
YoY Change 19.43% 32.64% 49.29%
% of Gross Profit 32.17% 44.42% 63.77%
Research & Development $80.90M $61.69M $37.65M
YoY Change 31.15% 66.78% -23.08%
% of Gross Profit 26.97% 33.91% 27.43%
Depreciation & Amortization $2.100M $1.800M $1.600M
YoY Change 16.67% 100.0% 100.0%
% of Gross Profit 0.7% 0.99% 1.17%
Operating Expenses $225.8M $149.1M $239.4M
YoY Change 51.44% 50.98% 120.58%
Operating Profit $76.60M $34.40M -$101.0M
YoY Change 122.67% -1957.45% 169.71%
Interest Expense $8.300M $7.900M $7.853M
YoY Change 5.06% 4.07% 4.65%
% of Operating Profit 10.84% 22.97%
Other Income/Expense, Net $6.600M $17.70M -$1.597M
YoY Change -62.71% 8750.0% -63.46%
Pretax Income $83.20M $52.10M -$102.6M
YoY Change 59.69% -983.05% 145.35%
Income Tax $3.600M $800.0K -$500.0K
% Of Pretax Income 4.33% 1.54%
Net Earnings $79.60M $51.30M -$102.1M
YoY Change 55.17% -967.58% 144.15%
Net Earnings / Revenue 26.32% 27.96% -73.77%
Basic Earnings Per Share $0.86 $0.56 -$1.12
Diluted Earnings Per Share $0.81 $0.54 -$1.12
COMMON SHARES
Basic Shares Outstanding 93.00M shares 91.40M shares 91.10M shares
Diluted Shares Outstanding 98.20M shares 94.80M shares 91.10M shares

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $948.3M $620.0M $524.1M
YoY Change 52.96% 21.87% 13.8%
Cash & Equivalents $415.1M $141.0M $72.78M
Short-Term Investments $533.2M $479.0M $451.3M
Other Short-Term Assets $27.50M $21.46M $24.15M
YoY Change 28.18% 31.63% 180.39%
Inventory $22.00M $12.02M $13.01M
Prepaid Expenses
Receivables $148.4M $95.36M $71.96M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.146B $748.8M $633.2M
YoY Change 53.07% 31.9% 23.26%
LONG-TERM ASSETS
Property, Plant & Equipment $44.60M $39.62M $36.66M
YoY Change 12.56% 110.76% 210.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $245.9M $223.9M $233.1M
YoY Change 9.83% -10.22% -15.64%
Other Assets $3.600M $5.500M $5.500M
YoY Change -34.55% 0.0% 22.22%
Total Long-Term Assets $369.4M $318.1M $324.5M
YoY Change 16.14% 16.25% 10.9%
TOTAL ASSETS
Total Short-Term Assets $1.146B $748.8M $633.2M
Total Long-Term Assets $369.4M $318.1M $324.5M
Total Assets $1.516B $1.067B $957.7M
YoY Change 42.06% 26.81% 18.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $137.1M $95.00M $68.30M
YoY Change 44.32% 55.74% 49.45%
Accrued Expenses $9.200M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $419.5M $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $573.0M $100.6M $72.00M
YoY Change 469.64% 62.87% 54.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $398.5M $393.4M
YoY Change -100.0% 5.17% 5.13%
Other Long-Term Liabilities $27.10M $17.92M $15.86M
YoY Change 51.27% -22.78% -25.17%
Total Long-Term Liabilities $27.10M $17.92M $15.86M
YoY Change 51.27% -95.54% -95.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $573.0M $100.6M $72.00M
Total Long-Term Liabilities $27.10M $17.92M $15.86M
Total Liabilities $684.4M $583.2M $87.87M
YoY Change 17.36% 25.71% -80.12%
SHAREHOLDERS EQUITY
Retained Earnings -$1.016B -$1.220B -$1.272B
YoY Change -16.78% -2.09% 2.51%
Common Stock $1.842B $1.704B $1.681B
YoY Change 8.14% 4.72% 4.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $831.2M $483.7M $409.3M
YoY Change
Total Liabilities & Shareholders Equity $1.516B $1.067B $957.7M
YoY Change 42.06% 26.81% 18.77%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income $79.60M $51.30M -$102.1M
YoY Change 55.17% -967.58% 144.15%
Depreciation, Depletion And Amortization $2.100M $1.800M $1.600M
YoY Change 16.67% 100.0% 100.0%
Cash From Operating Activities $121.6M $64.20M -$112.5M
YoY Change 89.41% 213.17% 192.31%
INVESTING ACTIVITIES
Capital Expenditures -$4.700M -$4.500M $3.900M
YoY Change 4.44% -2.17% 116.67%
Acquisitions
YoY Change
Other Investing Activities $98.10M $4.200M $44.90M
YoY Change 2235.71% -114.09% -181.19%
Cash From Investing Activities $93.40M -$300.0K $41.00M
YoY Change -31233.33% -99.13% -171.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.600M
YoY Change -83.89%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.10M 4.300M 2.600M
YoY Change 204.65% -30.65% -83.89%
NET CHANGE
Cash From Operating Activities 121.6M 64.20M -112.5M
Cash From Investing Activities 93.40M -300.0K 41.00M
Cash From Financing Activities 13.10M 4.300M 2.600M
Net Change In Cash 228.1M 68.20M -68.90M
YoY Change 234.46% -974.36% -13.23%
FREE CASH FLOW
Cash From Operating Activities $121.6M $64.20M -$112.5M
Capital Expenditures -$4.700M -$4.500M $3.900M
Free Cash Flow $126.3M $68.70M -$116.4M
YoY Change 83.84% 173.71% 188.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei City Area Code
CityAreaCode
(858)
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000914475
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-22705
dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
12780 El Camino Real
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0525145
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei Local Phone Number
LocalPhoneNumber
617-7600
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
NBIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
93254872 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
415100000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112300000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
530300000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
557300000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
533200000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
558200000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
148400000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
126600000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
22000000.0 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
17300000 USD
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
27500000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
16600000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
1146200000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
831000000.0 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
193500000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
299300000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
195200000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
299700000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
72100000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
74300000 USD
CY2020Q2 us-gaap Equity Securities Fv Ni Restricted
EquitySecuritiesFvNiRestricted
50700000 USD
CY2019Q4 us-gaap Equity Securities Fv Ni Restricted
EquitySecuritiesFvNiRestricted
55900000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44600000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41900000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3200000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3200000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3600000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2020Q2 us-gaap Assets
Assets
1515600000 USD
CY2019Q4 us-gaap Assets
Assets
1306000000.0 USD
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
137100000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
141300000 USD
CY2020Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
419500000 USD
CY2019Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
408800000 USD
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
16400000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15200000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
573000000.0 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
565300000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
84300000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
86700000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
27100000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17100000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
684400000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
669100000 USD
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000.0 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000.0 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000.0 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000.0 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93200000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
93200000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92300000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92300000 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1842200000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1768100000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4600000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1400000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1015700000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1132700000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
831200000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
636900000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1515600000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1306000000.0 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
302400000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
183500000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
539500000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
321900000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2400000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1600000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4500000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2700000 USD
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
80900000 USD
CY2019Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
61700000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
139200000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-66600000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
8300000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
7900000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
99400000 USD
CY2020Q2 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
46000000.0 USD
CY2019Q2 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
5000000.0 USD
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
46000000.0 USD
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
118100000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
96500000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
80800000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
214300000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
168300000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
225800000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
149100000 USD
us-gaap Costs And Expenses
CostsAndExpenses
404000000.0 USD
us-gaap Costs And Expenses
CostsAndExpenses
388500000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
76600000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
34400000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
135500000 USD
us-gaap Interest Expense
InterestExpense
16500000 USD
us-gaap Interest Expense
InterestExpense
15800000 USD
CY2020Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
11300000 USD
CY2019Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
21000000.0 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-5200000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
22700000 USD
CY2020Q2 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
3600000 USD
CY2019Q2 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
4600000 USD
nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
8300000 USD
nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
9200000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6600000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17700000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13400000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
16100000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
83200000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
52100000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
122100000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50500000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3600000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5100000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
79600000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
51300000 USD
us-gaap Net Income Loss
NetIncomeLoss
117000000.0 USD
us-gaap Net Income Loss
NetIncomeLoss
-50800000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6000000.0 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
900000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3200000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2600000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
85600000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
52200000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
120200000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48200000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.86
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.81
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93000000.0 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91400000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92800000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91200000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98200000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94800000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97600000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91200000 shares
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
700300000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
79600000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000000.0 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29500000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15800000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
831200000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
409300000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
51300000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
900000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17900000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4300000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
483700000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
636900000 USD
us-gaap Net Income Loss
NetIncomeLoss
117000000.0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3200000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
52300000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19100000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2700000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
831200000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
480800000 USD
us-gaap Net Income Loss
NetIncomeLoss
-50800000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2600000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33700000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6900000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2500000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
483700000 USD
us-gaap Net Income Loss
NetIncomeLoss
117000000.0 USD
us-gaap Net Income Loss
NetIncomeLoss
-50800000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
52300000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
33700000 USD
us-gaap Depreciation
Depreciation
4200000 USD
us-gaap Depreciation
Depreciation
3400000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10000000.0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
9300000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
700000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
700000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-5200000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
22700000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
700000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-600000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21800000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
39100000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4700000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1200000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5100000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7700000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
1400000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-11300000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
157100000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48300000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
54700000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000000.0 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
288600000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
235900000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
421200000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
339700000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8400000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
126600000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
40700000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19100000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6900000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19100000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6900000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
302800000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-700000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115500000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147200000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
418300000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146500000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
900000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
900000 USD
us-gaap Interest Paid Net
InterestPaidNet
5800000 USD
us-gaap Interest Paid Net
InterestPaidNet
5800000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
400000 USD
nbix Number Of Irish Subsidiaries
NumberOfIrishSubsidiaries
2 subsidiary
CY2020Q2 us-gaap Debt Securities Available For Sale Accrued Interest Threshold Period Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff
P90D
us-gaap Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts
FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts
<div style="margin-top:4pt;margin-bottom:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Allowance for Credit Losses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued interest receivables on debt securities available-for-sale totaled $3.7 million at June 30, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the six months ended June 30, 2020.</span></div>
CY2020Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
3700000 USD
us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0 USD
CY2020Q2 nbix Debt Securities Available For Sale Position Number Of Positions
DebtSecuritiesAvailableForSalePositionNumberOfPositions
158 security
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
17 security
CY2020Q2 us-gaap Investments
Investments
1197400000 USD
CY2019Q4 us-gaap Investments
Investments
1029300000 USD
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
15800000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
14100000 USD
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1800000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1500000 USD
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4400000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1700000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
22000000.0 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
17300000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
415100000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112300000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3200000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3200000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
418300000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
115500000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
5000000.0 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
3900000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
11600000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
4300000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
3300000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4300000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
10600000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10900000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
11200000 USD
CY2020Q2 nbix Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
79700000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
128300000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
34800000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
93500000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9200000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
84300000 USD
CY2020Q2 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced
28300000 USD
CY2020Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
517500000 USD
CY2019Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
517500000 USD
CY2020Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
6200000 USD
CY2019Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
6900000 USD
CY2020Q2 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
91800000 USD
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
101800000 USD
CY2020Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
419500000 USD
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
408800000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
79600000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
51300000 USD
us-gaap Net Income Loss
NetIncomeLoss
117000000.0 USD
us-gaap Net Income Loss
NetIncomeLoss
-50800000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93000000.0 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91400000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92800000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91200000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98200000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94800000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97600000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91200000 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.86
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.81
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56

Files In Submission

Name View Source Status
0000914475-20-000018-index-headers.html Edgar Link pending
0000914475-20-000018-index.html Edgar Link pending
0000914475-20-000018.txt Edgar Link pending
0000914475-20-000018-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image61.jpg Edgar Link pending
image71.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nbix-20200630.htm Edgar Link pending
nbix-20200630.xsd Edgar Link pending
nbix-20200630exhibit101.htm Edgar Link pending
nbix-20200630exhibit102.htm Edgar Link pending
nbix-20200630exhibit103.htm Edgar Link pending
nbix-20200630exhibit311.htm Edgar Link pending
nbix-20200630exhibit312.htm Edgar Link pending
nbix-20200630exhibit32.htm Edgar Link pending
nbix-20200630_cal.xml Edgar Link unprocessable
nbix-20200630_def.xml Edgar Link unprocessable
nbix-20200630_htm.xml Edgar Link completed
nbix-20200630_lab.xml Edgar Link unprocessable
nbix-20200630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending